In this issue:
Daratumumab beneficial regardless of timing of first relapse in RRMM
Second-line DRd effective in the real world
PERSEUS: PFS benefit to daratumumab quadruplet in newly diagnosed transplant-eligible disease
Predictors of unsustained MRD negativity
Risk factors of MRD resurgence after achieving undetectable MRD
Active surveillance preferred by clinicians for high-risk smoldering MM
Teclistamab bests current therapies in triple-class exposed RRMM
Teclistamab effective in real-world RRMM population
GMMG-HD6: front-line elotuzumab fails to prolong PFS vs standard therapy
Pre-transplant CHIP linked to cardiovascular disease
Please login below to download this issue (PDF)